GLMD

Galmed Pharmaceuticals Ltd.
Data: 2026-01-30
$0.71
Price
-5.79%
Change
$3.5
52W High
$0.7
52W Low

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.

Quick Stats
Jan 30, 2026

52.2

AI Score

HOLD

0.87

Volume Ratio

Apr 01, 2026

Next Earnings

10

+ve Days (30d)

20

-ve Days (30d)

GLMD Stock Summary

Last updated Jan 30, 2026

GLMD is currently trading at $0.71, positioned below its 200-day moving average of $1.36, suggesting bearish momentum. The stock has a 52-week range of $0.7 to $3.5.

Technical Analysis: The 50-day moving average stands at $0.89, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 35.354, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.194, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates GLMD at 52.2/100 with a HOLD recommendation.

GLMD (Galmed Pharmaceuticals Ltd.) Indicators

Last updated Jan 30, 2026

Indicator Value
RSI(14) 35.354
CMF (20) -0.194
ROC (10) -9.381
ADX (14) 12.099
Indicator Value
MACD (12,26,9) -0.041
AROONOSC (14) -100.0
WILLAMS %R (14) -94.444
MFI (14) 37.428
GLMD Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

GLMD Price vs Max Options Open Interest
GLMD Max Change In Options Open Interest

GLMD Options - Sort by Max open Interest (near term)

1st February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

GLMD Daily Out of Money Options - Sort by Max open Interest (near term)

1st February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

GLMD Daily In the Money Options - Sort by Max open Interest (near term)

1st February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

GLMD Most Active Options by Volume(near term)

1st February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI
Ask PC Delta Vega Volatility % change Track

Galmed Pharmaceuticals Ltd. is not trading above both 50 Day and 200 Day SMA which is considered Bearish.

GLMD Moving Averages Analysis

GLMD (Galmed Pharmaceuticals Ltd.) Simple Moving Averages

Moving Averages are last updated Jan 30, 2026

Days MA
10 0.8
20 0.81
30 0.82
50 0.89
100 1.14
200 1.36

GLMD Fundamental Analysis

P/E (Forward) 0
P/E (Trailing) --
Market Cap ($) 4.0 million
Earnings/Share ($) -3.44
Net Proft Margin (%) 0
Dividend/Share ($) --
EPS Estimate Current Year ($) -2.31
EPS Estimate Next Year ($) -0.85
WallStreet Target Price ($) 12
Most Recent Quarter